คลังวิทยาศาสตร์

Urolithin A

ระดับหลักฐานระดับหลักฐาน E

ดูบันทึกหลักฐานอิสระที่อธิบายด้วยภาษาที่เข้าใจง่าย ระดับหลักฐานแต่ละระดับตอบคำถามวิจัยที่กำหนดและไม่ใช่คะแนนของผลิตภัณฑ์

ทบทวนล่าสุด: 22 Aug 2026

IN PLAIN LANGUAGE

Why people are interested

A gut-microbial metabolite studied in mitochondrial quality-control biology. Measured circulating metabolites and mechanistic biomarkers do not establish mitophagy benefit, age reversal or a clinical outcome.

Outcome map

One ingredient. Different questions.

Each row answers a separate question; evidence strength can differ by outcome.

01
Human lifespan or validated healthspan
No completed human intervention reviewed demonstrated longer lifespan or an improvement in a validated healthspan endpoint.
Level E
02
Circulating exposure
One exact high-purity direct formulation produced greater measured metabolite exposure than one tested juice challenge; exposure is not efficacy.
Level B
03
Six-minute walk distance
The corrected two-trial estimate favored Urolithin A but its confidence interval crossed zero, leaving the result statistically inconclusive and low certainty.
Level C
04
Peak power and ATP production
The named primary outcomes did not significantly improve in their exact trial contexts, which blocks a broad energy or power benefit claim.
Level B
05
Torque or contraction endurance
Selected exploratory secondary signals exist, but small studies, null primary outcomes and multiplicity limits prevent a firm benefit conclusion.
Level C
06
Short-term tolerability
Selected short trials did not show a consistent serious treatment-related pattern under their exact conditions; universal or long-term safety is not established.
Level B

How it may work

What people have studied

One exact high-purity direct-Urolithin-A formulation produced greater circulating conjugated-metabolite exposure than one tested pomegranate-juice challenge, but exposure is not efficacy. The corrected two-trial six-minute-walk synthesis was statistically inconclusive and low certainty; exploratory muscle, recovery and immune-cell signals coexist with null primary and other outcomes. No completed human intervention demonstrates longer lifespan or validated healthspan.

What to consider

Selected direct-Urolithin-A trials did not show a consistent serious treatment-related pattern over their short study periods. That does not establish long-term, rare-event, interaction, pregnancy, pediatric or medically complex safety, or transfer to another source or finished product.

Local pathway

This science review does not establish a Thailand market route. Ingredient source, formulation and finished-product status require separate official confirmation.

แหล่งข้อมูล